Liver Cancer News & Features
The risk of disease recurrence in liver cancer patients who have undergone a liver transplant can now be more accurately calculated, thanks to new tool.
An interventional x-ray guidance device approved by the U.S. Food and Drug Administration in 2013 may have the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.
AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer.
Triclosan, a popular antimicrobial agent in soaps, detergents, and plastics, has been found to promote liver cancer in mice.
Liver tumor cells do not respond to sorafenib if they have a less differentiated phenotype, known as the mesenchymal type, and express CD44, according to a new study.
Liver Cancer Videos
Liver Cancer Clinical Trials
- New treatment method shrinks ovarian cancer tumors and improves chemotherapy effectiveness
- Epigenetic signatures differentiate triple negative breast cancers
- Women educated on overdiagnsosis are less likely to want mammogram
- Novel drug approved for multiple myeloma
- Radiation therapy used most often for prostate cancer regardless of decision-making factors
- Farydak (panobinostat) now FDA-approved for multiple myeloma
- ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer
- Urine test could help to guide treatment of bladder cancer
- Multiple studies are exploring whether e-cigarettes help smokers quit or continue smoking
- Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|